IXICO Plc (LON:IXI), the digital technologies company serving neuroscience, has signed amendments to current contracts that expand the clinical trial services provided to two biopharmaceutical companies.
The change orders have increased the combined contracts’ value by £500,000 or roughly 24% to £2.35mln.
IXICO said the changes reflect an expansion in the scope of PET and MRI neuroimaging clinical trial services, with IXICO providing additional specialist services during the contract period.
The Phase II study contracts in Alzheimer's disease and Huntington's disease were previously announced in July and September 2017, respectively.
The scope of services that IXICO provides can be expanded or extended at any time during the life of a clinical trial, so change orders can occur during the course of multi-year contracts, IXICO explained.
Giulio Cerroni, the chief executive officer of IXICO, expressed delight at the extension of the two contracts.
“This underscores the importance of working closely with our biopharmaceutical clients, particularly during the initial phase of a contract, to maximise the value our specialist technologies and services can provide," he added.